- Regulatory approvals and Sinopharm procurement deal will allow first phase of vaccine rollout to begin in coming weeks
- Major logistical obstacles and vaccine scepticism will mean wider public rollout, targeting 70% of population, is protracted
- Imminent beginning of vaccination programme will ensure government remains unwilling to impose major restrictions
The government announced it had granted emergency use approval (EUA) for the coronavirus (COVID-19) vaccine developed by AstraZeneca and Oxford University on 16 January. Two days later, the Drug Regulatory Authority approved a second vaccine, developed by the Chinese state-owned manufacturer Sinopharm.
Falanx Assynt is a global intelligence consultancy and leading provider of geopolitical, strategic and business risk analysis since 2003. Falanx Assynt is part of Falanx Group Ltd (LON:FLX) which, through its subsidiaries, provides cyber defence and intelligence services to blue chip and government clients worldwide.